Skip to main content
. 2018 Jul 18;42(4):1875–1884. doi: 10.3892/ijmm.2018.3782

Figure 3.

Figure 3

Effect of piperlongumine (PL) on the expression of synaptic proteins and NMDAR signalling proteins. (A and B) Western blot analysis and quantitative analysis of the expression of synaptic proteins [gephyrin, vesicular GABA transporter (VGAT), glutamate decarboxylase 65/67 (GAD65/67), postsynaptic density protein 95 (PSD95), vesicular glutamate transporter 1 (VGLUT1), vesicular glutamate transporter 2 (VGLUT2) and synaptophysin, aged vehicle; n=5, aged PL; n=7] in hippocampal homogenates of aged mice treated with the vehicle or PL. (C and D) Western blot analysis and quantitative analysis of the expression of NMDAR signalling proteins [glutamate receptor 1 (GluR1), N-methyl-D-aspartate receptor subtype 2B (NR2B), p-NR2B, extracellular signal-regulated kinase (ERK)1/2, p-ERK1/2, calcium/calmodulin-dependent protein kinase type II α (CaMKIIα), p-CaMKIIα, cAMP response element binding protein (CREB) and p-CREB, aged vehicle; n=5, aged PL; n=7] in hippocampal homogenates of aged mice treated with the vehicle or PL. *P<0.05 and **P<0.01, significant differences from the aged vehicle, as shown by the Student's t-test. Data are presented as the means ± SEM.